| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | Ins2 |
| Uniprot No | P01326 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-110aa |
| 氨基酸序列 | FVKQHLCGSHLVEALYLVCGERGFFYTPMSRREVEDPQVAQLELGGGPGAGDLQTLALEVAQQKRGIVDQCCTSICSLYQLENYCN |
| 预测分子量 | 16.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Ins2重组蛋白的3篇参考文献的简要总结(示例为虚构文献，供参考格式)：
1. **文献名称**：*Efficient Expression and Purification of Recombinant Mouse Ins2 in E. coli*
**作者**：Zhang, Y. et al.
**摘要**：该研究通过优化大肠杆菌表达系统，成功实现小鼠Ins2蛋白的高效可溶性表达，并建立了一步法亲和层析纯化流程，为糖尿病动物模型研究提供高纯度重组蛋白。
2. **文献名称**：*Structural Analysis of Humanized Ins2 Mutants for Beta Cell Dysfunction Studies*
**作者**：Tanaka, K. & Müller, W.
**摘要**：通过定点突变技术构建人源化Ins2重组蛋白，结合X射线晶体学解析其空间结构，揭示了特定氨基酸残基在胰岛素分泌异常中的潜在作用机制。
3. **文献名称**：*Recombinant Ins2 Protein Nanoparticles for Oral Insulin Delivery*
**作者**：Chen, L. et al.
**摘要**：开发基于Ins2重组蛋白与壳聚糖的纳米递送系统，证明其在小鼠模型中能有效提高口服胰岛素生物利用度，降低餐后血糖水平。
---
**注**：以上文献为模拟示例，实际引用时建议通过PubMed/Web of Science等平台以关键词"Ins2 recombinant protein"+"expression"/"delivery"/"structure"等检索近年研究。
**Background of Recombinant Ins2 Protein**
Insulin 2 (Ins2) is a critical peptide hormone encoded by the *INS2* gene, primarily involved in glucose homeostasis. In mammals, insulin is produced as a prohormone (proinsulin) in pancreatic β-cells, comprising two polypeptide chains (A and B) linked by a C-peptide. Ins2 is one of two insulin isoforms in rodents (alongside Ins1), while humans express a single insulin gene homologous to rodent *Ins2*. Its role in regulating blood sugar via glucose uptake and metabolism has made it a focal point in diabetes research.
Recombinant Ins2 protein refers to synthetic insulin produced through genetic engineering. Historically, insulin therapy relied on animal-derived insulin, which posed risks of immunogenicity and limited supply. The advent of recombinant DNA technology in the 1980s enabled large-scale production of human-compatible insulin. By inserting the *INS2* gene into expression vectors (e.g., *E. coli* or yeast), proinsulin is biosynthesized, purified, and enzymatically processed to yield active insulin.
Recombinant Ins2 retains the biological activity of native insulin, binding to insulin receptors to trigger downstream signaling. Beyond diabetes treatment, it serves as a research tool for studying β-cell function, insulin resistance mechanisms, and metabolic disorders. Its recombinant form ensures consistency, scalability, and reduced batch-to-batch variability, addressing therapeutic and experimental demands.
Recent advances include engineered Ins2 analogs with modified pharmacokinetics (e.g., rapid-acting or long-acting insulins) and fusion proteins for targeted delivery. Additionally, recombinant Ins2 is pivotal in developing *in vitro* disease models and screening antidiabetic drugs. As diabetes prevalence rises globally, recombinant Ins2 remains central to both clinical and basic research, underscoring its therapeutic and scientific significance.
×
